Topic summary

Amylin receptor signalling and satiety

Pharmacology › Receptor biology tirzepatide semaglutide amylin analogues Wiki

This is a generated summary. It shows the 5 most-liked posts from a topic of 27, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

t.nardoneTL3Regular19 Oct 2025#3

Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by outline_first on 1 Feb 2026.

10 Jan 2026 — coldchain_liu: Replaced an unsourced figure with the published one and cited it.
24 Feb 2026 — r.venkatesan: Removed a claim that the cited source did not support.
1 Feb 2026 — outline_first: Clarified the distinction that was causing repeat questions below.

Editors: coldchain_liu, r.venkatesan, outline_first

Species differences: rodent studies show the same compounds produce effects in rodents that predict human effects reasonably well for semaglutide and tirzepatide. The track record is less clear for novel compounds with less human data.

18 likes 9mo

n.rowntreeTL3Regular22 Oct 2025#7

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

24 likes 9mo

trough_indexTL3Regular28 Oct 2025#16

s.bergstrom, post #11: post #10 is right about the mechanism and I think understates the practical bit. Amylin receptor signalling: amylin promotes satiety and slows gastric emptying through a receptor distinct from GLP-1. The hypothesis behind combination therapy is two complementary satiety mechanisms. Go to post

On post #12 — agreed on the reasoning, with one qualification.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

23 likes in reply to #11 9mo

e.verhoevenTL2 Moderator31 Oct 2025#21

KTurkington, post #18: GLP-1 receptor signalling: the GLP-1 receptor is expressed on beta cells (insulin secretion), on neurons (appetite and gastric motility), and on myocardium (contractility). Different tissues respond to the same signal in different ways. Go to post

Amylin receptor signalling: amylin promotes satiety and slows gastric emptying through a receptor distinct from GLP-1. The hypothesis behind combination therapy is two complementary satiety mechanisms.

19 likes in reply to #18 9mo

a.asanteTL2 Moderator2 Nov 2025#25

r.laurent, post #24: Picking up post #21: that is the part I would want checked first. Pharmacological class effects: all GLP-1 agonists slow gastric emptying and suppress appetite. Those are class effects, not unique to one compound. Effects that differ between compounds are usually about potency or receptor selectivity. Go to post

26 likes in reply to #24 9mo

Read the full topic (27 posts)

This topic was referenced in

Biased agonism: a real phenomenon, an over-used explanationPharmacology › Receptor biology · 135 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
GLP-1 receptor distribution: central and peripheral Pharmacology › Receptor biology semaglutide amylin analogues retatrutide long read Posting this under the heading it deserves: GLP-1 receptor distribution: central and peripheral Everything below is what sits behind that. A documentation question rather than an analytical one. I have a…	+90	98	30k	22h
Why appetite effects are mostly central Pharmacology › Receptor biology amylin analogues tirzepatide semaglutide long read Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…		2	56k	16mo
Revisiting: GLP-1 receptor distribution: central and peripheral Pharmacology › Receptor biology amylin analogues tirzepatide retatrutide long read Revisiting: GLP-1 receptor distribution: central and peripheral — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I have a…	+61	66	15k	8mo
Biased agonism: a real phenomenon, an over-used explanation Pharmacology › Receptor biology semaglutide retatrutide long read tirzepatide Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…	+130	135	23k	16mo
GIP receptor agonism and the argument about direction — does this still hold? Pharmacology › Receptor biology long read amylin analogues retatrutide Solved GIP receptor agonism and the argument about direction — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Working through the identity arithmetic…	+10	14	15k	16h

Related topics — sharing the tags tirzepatide, semaglutide, amylin analogues

Topic	Participants	Replies	Views	Activity
What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema amylin analogues Solved What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med…	+83	91	46k	1d
Half-life, steady state, and accumulation worked through Pharmacology › Pharmacokinetics semaglutide liraglutide tirzepatide Wiki Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…	+115	130	44k	13mo
SURPASS-2 and the comparator dose question that will not go away Compounds › Tirzepatide SURPASS programme randomised trial effect size SURMOUNT programme SURPASS-2 and the comparator dose question that will not go away — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+101	111	1.5k	18mo
Cagrilintide's dosing interval and the pharmacokinetics behind it Compounds › Cagrilintide & amylin analogues effect size randomised trial amylin analogues cagrisema Solved Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SELECT ( N Engl J Med ,…	+98	105	24k	10mo
Peak-to-trough ratio at steady state for a weekly agent — the long version Pharmacology › Pharmacokinetics semaglutide missed dose tirzepatide worked example Under review Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. I would like to understand what this number means…	+57	61	708	1d